Company intelligence / Profile preview

Lumigenex

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Lumigenex has developed and commercialized a proprietary TRFIA-based point-of-care testing platform for rapid diagnostics in cardiology, women's health, infectious disease, oncology, and drugs of abuse. The company holds exclusive patents for its technology and has established global distribution. No clinical trial results are reported as the products are diagnostic devices rather than therapeutics.

Therapeutic areas: OncologyInfectious DiseasesPsychiatryCardiovascularWomen's Health
Modalities: DeviceDiagnostic assay (Time Resolved Fluorescence Immunoassay)Nanotechnology-based diagnostic platform
Industry: Protein Biomarker Diagnostics

Partnerships

Exclusive license agreement with Kimberly-Clark Corporation for certain patentsGlobal strategic partners in distribution/manufacturing

Beyond the preview

Go deeper on Lumigenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumigenex.

Explore the full profile